FAYUVI
Live / Applied — First extension granted (statement of use) (as of 06 Oct 2025)
What this means for you
Not registered yet, but its 17 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98806913
- Mark type
- Stylized text
- Filed
- 17 Oct 2024
- Published for opposition
- 06 May 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 042 — Scientific and technological services: Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical research and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, genetic, central nervous system, and lysosomal storage diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery
Owner
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
Prosecution history
- 07 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Oct 2025 — SOU EXTENSION 1 GRANTED
- 06 Oct 2025 — SOU EXTENSION 1 FILED
- 06 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 May 2025 — PUBLISHED FOR OPPOSITION
- 30 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 31 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 31 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 25 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 25 Mar 2025 — NON-FINAL ACTION E-MAILED
- 25 Mar 2025 — NON-FINAL ACTION WRITTEN